Mirum’s ATEBRIOZ reduced abnormal bone volume in young children, but will the FDA expand its approval?
Mirum's ATEBRIOZ reduced abnormal bone volume in children aged 6 to under 12 with FOP. Can the results support FDA label expansion in 2027?
Pharma & Biotech
Pharma & Biotech
Why Mirum Pharmaceuticals and Incyte’s zilurgisertib data could reset expectations in FOP treatment
Read how Mirum and Incyte’s zilurgisertib Phase 2 data could reshape FOP treatment, FDA review risk and rare disease strategy.